X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ABBOTT INDIA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ABBOTT INDIA SANOFI INDIA/
ABBOTT INDIA
 
P/E (TTM) x 38.3 36.9 103.7% View Chart
P/BV x 7.2 9.5 76.0% View Chart
Dividend Yield % 0.5 0.7 72.4%  

Financials

 SANOFI INDIA   ABBOTT INDIA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
ABBOTT INDIA
Mar-18
SANOFI INDIA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs4,9456,110 80.9%   
Low Rs3,9013,996 97.6%   
Sales per share (Unadj.) Rs1,081.81,552.2 69.7%  
Earnings per share (Unadj.) Rs141.6188.8 75.0%  
Cash flow per share (Unadj.) Rs185.9196.4 94.7%  
Dividends per share (Unadj.) Rs33.0055.00 60.0%  
Dividend yield (eoy) %0.71.1 68.5%  
Book value per share (Unadj.) Rs868.8796.6 109.1%  
Shares outstanding (eoy) m23.0321.25 108.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.13.3 125.6%   
Avg P/E ratio x31.226.8 116.7%  
P/CF ratio (eoy) x23.825.7 92.5%  
Price / Book Value ratio x5.16.3 80.3%  
Dividend payout %23.329.1 80.0%   
Avg Mkt Cap Rs m101,862107,376 94.9%   
No. of employees `0003.23.3 97.5%   
Total wages/salary Rs m3,6853,937 93.6%   
Avg. sales/employee Rs Th7,691.99,929.3 77.5%   
Avg. wages/employee Rs Th1,137.71,185.1 96.0%   
Avg. net profit/employee Rs Th1,006.51,207.7 83.3%   
INCOME DATA
Net Sales Rs m24,91432,985 75.5%  
Other income Rs m8071,170 69.0%   
Total revenues Rs m25,72134,155 75.3%   
Gross profit Rs m5,3725,245 102.4%  
Depreciation Rs m1,022162 631.3%   
Interest Rs m1138 28.8%   
Profit before tax Rs m5,1466,215 82.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8862,203 85.6%   
Profit after tax Rs m3,2604,012 81.3%  
Gross profit margin %21.615.9 135.6%  
Effective tax rate %36.635.4 103.4%   
Net profit margin %13.112.2 107.6%  
BALANCE SHEET DATA
Current assets Rs m14,43222,655 63.7%   
Current liabilities Rs m6,0106,681 90.0%   
Net working cap to sales %33.848.4 69.8%  
Current ratio x2.43.4 70.8%  
Inventory Days Days6165 94.0%  
Debtors Days Days2829 97.7%  
Net fixed assets Rs m7,991835 956.5%   
Share capital Rs m230213 108.4%   
"Free" reserves Rs m19,77816,715 118.3%   
Net worth Rs m20,00816,928 118.2%   
Long term debt Rs m00-   
Total assets Rs m27,77024,162 114.9%  
Interest coverage x468.8163.7 286.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.4 65.7%   
Return on assets %11.816.8 70.3%  
Return on equity %16.323.7 68.7%  
Return on capital %25.836.9 69.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,306369 1,711.1%   
Fx outflow Rs m5,2573,807 138.1%   
Net fx Rs m1,049-3,438 -30.5%   
CASH FLOW
From Operations Rs m4,3511,527 284.9%  
From Investments Rs m-787-2,148 36.6%  
From Financial Activity Rs m-1,884-1,024 183.9%  
Net Cashflow Rs m1,680-1,646 -102.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 7.9 182.3%  
FIIs % 14.6 0.1 14,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.1 61.4%  
Shareholders   15,184 18,270 83.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Dec 17, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ELDER PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS